Gastric Ulcers Market Overview

The global Gastric Ulcers market is estimated to be worth over USD 6.96Bn in 2033 and is expected to grow at CAGR of 4.3% during the forecast period (2024-2033). Gastric ulcers, marked by open sores that develop on the inner lining of the stomach, offer a notable global health concern. These ulcers can result from varied factors, comprising infection with Helicobacter pylori bacteria, extended use of nonsteroidal anti-inflammatory drugs (NSAIDs), exorbitant alcohol consumption, and stress. The incidence of gastric ulcers is extensive, affecting millions of people across the world, with varying degrees of severity.

The global market for gastric ulcer treatment surrounds anextensive spectrum of pharmaceuticals, medical interventions, and supportive therapies. Proton pump inhibitors (PPIs) and histamine-2 receptor blockers (H2 blockers) are commonly prescribed medications that mitigate stomach acid production, offering relief and supporting ulcer healing. In addition to that, antibiotics is likely to be prescribed to eliminate H. pylori infection. The market also involves antacids, cytoprotective agents, and lifestyle modifications focusing at managing symptoms and avoiding ulcer recurrence.

The demand for effective and advanced therapies has fueled research and development activities in the pharmaceutical industry. Continuing efforts aim on developing novel drugs with enhanced efficiency, lesser side effects, and quicker healing times. Along with that, innovations in diagnostic techniques, such as endoscopy and non-invasive imaging, contribute to early detection and management of gastric ulcers.

Geographically, the market for gastric ulcer treatments showcases variations in prevalence and healthcare infrastructure. Emerging regions is estimated towitness challenges associated with access to healthcare and affordability of medications, while developed regions witness a more robust market with advanced medical facilities and escalated healthcare expenditure.

Since the global population ages and lifestyles evolve, the prevalence of gastric ulcers is anticipated to continue, underlining the prominence of persistent research, education, and access to effective treatments. The market's growth is influenced by factors such as technological innovations, soaring healthcare awareness, and strategic collaborations between pharmaceutical companies, healthcare providers, and research institutions aiming to address the multifaceted challenges related to gastric ulcers on a global scale.

Figure 1. Gastric Ulcers: Market Size

Get more details on this report - Request Free Sample

Key Market Insights &Current Market Landscape

The Helicobacter pylori bacterium (H. pylori) is the primary cause of peptic ulcers. The discovery of this micro-organism in 1983 transformedseveral aspects of gastroenterology, comprising the treatment of stomach ulcers.H. pylori infection is unusual in young Australians and occurs in 15 to 20% of Australians aged over 25.H. pylori directly induce one-third of stomach ulcers and is a contributing factor in around three-fifths of cases. Other disorders induced by this infection comprise inflammation of the stomach (gastritis) and dyspepsia (indigestion).

Diagnosing a stomach ulcer is done using an array of methods, including endoscopy – a thin flexible tube is threaded down the esophagus into the stomach under light anesthesia. The endoscope is fitted with a video capture device and increasingly detailed images of the stomach lining can be obtained. If a gastric ulcer has been found, the endoscopy must be repeated after treatment to ensure healing and exclude the possibility of cancer. Secondly, biopsy – a small tissue sample is taken during an endoscopy and tested in a laboratory. This biopsy should always be done if a gastric ulcer is found. Other than that, C14 breath test – checks for the presence of H. pylori. The bacteria convert urea into carbon dioxide. The test involves swallowing an amount of radioactive carbon (C14) and testing the air exhaled from the lungs. A non-radioactive test can be used for children and pregnant women.

Market Dynamics

Market Drivers

Increasing Investment for Healthcare Infrastructure

Since private entities and governments assignsignificant funds to improve healthcare facilities, there is a direct positive influence on the diagnosis, treatment, and management of gastric ulcers. Enhanced healthcare infrastructure translates into improved accessibility to medical services, diagnostic tools, and medications, fostering early detection and thorough care for individuals suffering from gastric ulcers.

Investments in state-of-the-art medical facilities and the incorporation of advanced diagnostic technologies allow healthcare providers to conduct timely and precise assessments of gastric ulcers, supportingswift intervention. In addition to that, well-equipped healthcare centres improve the overall patient experience, ensuring efficacy and effective treatment regimens.

Along with that, the elevated investment oftentimes correlates with increased research and development activities, fuelling pharmaceutical firms to innovate and introduce novel therapies for gastric ulcer management. The synergy between improved healthcare infrastructure and advanced medical solutions contributes to the growth and evolution of the global gastric ulcers market, addressing the evolving healthcare needs of populations across the world and ultimately enhancing patient outcomes.

Market Restraints

With regard to numerous advantages of Gastric Ulcers, the market faces several challenges due to the unique characteristics and requirements associated with these potent pharmaceutical products. Some of the key market challenges include:

• High Treatment Costs: The global gastric ulcers market witnessed a restraint in the form of increased treatment costs related toinnovative medications, diagnostic procedures, and medical interventions. Affordability issues is likely to limit access to optimal care, specifically in regions with lower socioeconomic status, hampering widespread adoption of effective treatments.
• Adverse Effects of Medications: Some pharmaceutical interventions for gastric ulcers, such as proton pump inhibitors (PPIs), is estimated to associate with adverse effects, comprising long-term complications like osteoporosis and potential interactions with other medications. Concerns over adverse effects is likely to influence patient compliance and limit the long-term use of certain medications, impacting the overall efficacy of treatment strategies.

Market Opportunity

Increase in the Number of Research and Development Activities

As the understanding of the complex etiology and underlying mechanisms of gastric ulcers surges, intensified R&D efforts lead the way for advanced and more effective treatment modalities. Continuing research not only improves the existing therapeutic landscape but also nurtures the evolution of novel pharmaceuticals and targeted therapies with enhanced efficacy and mitigated side effects.

Innovation in diagnostic technologies and approaches is another facet of R&D that benefits the gastric ulcers market. Innovative diagnostic tools allow more accurate and early detection of gastric ulcers, promoting timely intervention and personalized treatment strategies.

Collaborations between pharmaceutical firms, academic institutions, and research companies contribute to a dynamic realm that propels the translation of scientific discoveries into practical clinical applications. This collaborative synergy fosters the exploration of promising therapeutic targets, biomarkers, and treatment regimens, ultimately expanding the range of alternatives available to healthcare professionals.

Investments in R&D not only fuel product development but also tackle unmet needs in gastric ulcer management. The persistent influx of novel solutions through research activities not only enhances patient outcomes but also sustains the growth and competitiveness of the global gastric ulcers market.

Market Trends

• Shift towards Precision Medicine: The global gastric ulcers market is undergoing a trend towards personalized medicine, where treatment strategies are customized to individual patient characteristics. Advancements in molecular diagnostics and genetic profiling allow for a more customized approach to gastric ulcer management, maximizing therapeutic outcomes and minimizing adverse effects.
• Rising Adoption of Minimally Invasive Procedures: Minimally invasive procedures, such as endoscopic therapies, are gaining popularity in the treatment of gastric ulcers. These techniques provide reduced recovery times, lesser complication rates, and enhanced patient satisfaction compared to conventional surgical interventions. The trend towards minimally invasive procedures aligns with a growing emphasis on enhancing patient experience and promoting faster, less invasive treatment options for gastric ulcers.

Gastric Ulcers Market: Key Segments

By Drug Class

• Proton Pump Inhibitors (PPI)
• H2 Antagonists
• Antacids
• Antibiotics
• Cytoprotective Agents
• Others

By Diagnosis

• Stool Test
• Endoscopy
• Imaging Tests
• CT scan
• X-ray
• Others
• Blood Tests
• Others

By Route of Administration

• Oral
• Parenteral
• Others

By End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

By Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America

Figure 4. Gastric Ulcers Market: Distribution by Region

Get more details on this report - Request Free Sample

Gastric Ulcers Market: Regional Analysis

North America dominates the gastric ulcers market because of the rising prevalence of gastric ulcers and technological advancement in the treatment in this region. Additionally, rising healthcare expenditure and the presence of major key players will further propel the market’s growth rate.

Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing geriatric population and surging level of disposable income in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market’s growth rate in this region.

Leading Gastric Ulcers Developers

Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape, market size and future opportunities associated with the Gastric Ulcersmarket, during the given forecast period. Further, the market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the biopharmaceutical industry. Key takeaways of the Gastric Ulcersmarket are briefly discussed below.

The report includes the list of players operating in the global Gastric Ulcers market. Some of the key players include:

• Allergan (Ireland)
• Allergan (Ireland)
• AbbVie Inc. (U.S.)
• Amgen Inc. (U.S.)
• AstraZeneca (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Bayer AG (Germany)
• Boehringer Ingelheim International GmbH. (Germany)
• Dr. Reddy's Laboratories Ltd. (India)
• Eli Lilly and Company (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Gilead Sciences, Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Hikma Pharmaceuticals PLC (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Lupin (India)
• Merck & Co., Inc. (U.S.)
• Mylan N.V. (U.S.)
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• Sanofi (France)
• Teva Pharmaceutical Industries Ltd. (Ireland)

Key Developments

• In August 2021, Pharma major Dr Reddy's Laboratories launched generic Chlordiazepoxide Hydrochloride and Clidinium Bromide capsules used for treatment of stomach ulcers, irritable bowel syndrome and inflammation of the colon, in the US market.

Scope of the Report

The market report presents an in-depth analysis of the various firms / organizations that are engaged in this market, across different segments, as defined in the below table: